According to a research study focused on magic mushrooms in Canada, nearly 80% of the participants expressed their belief that psilocybin, the active compound in magic mushrooms, should be medically available for patients experiencing distress. Moreover, about two-thirds of these Canadian participants concurred that psilocybin should be legally obtainable for those in need.
Beyond advocating for the increased access to this substance, an impressive 84.8 percent of participants believe that the public health system should bear the expenses of such treatments. A majority of Canadians view psilocybin as a legitimate therapeutic option, especially for alleviating end-of-life distress.
[toc]
Primary Findings:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a viable medical solution for dealing with end-of-life existential distress.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind studies reported immediate and lasting benefits, with effects enduring for at least six months.
Exploring Existential Distress
Existential distress, similar to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with the reality of their mortality. Patients may experience feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose. This form of distress particularly impacts patients with life-threatening conditions, potentially inciting a desire to hasten death or contemplate suicide.
Typically, individuals facing terminal illnesses or substantial life changes are the ones most likely to experience this type of distress. It significantly impacts their mental health and overall quality of life.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may require multiple sessions and may not be effective for everyone.
The uncertainty about the effectiveness of such therapy is a key reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin for Therapeutic Purposes
Over the past two decades, preliminary clinical trials have emphasized the potential advantages of psychedelic substances in addressing complex mental health disorders. Psilocybin, notably, has demonstrated rapid and sustained relief from existential anxiety in patients approaching the end of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments do not succeed, Health Canada revised the Special Access Program in 2022. This revision enables healthcare professionals to apply for controlled substances for patient use.
Canadian Support for Access to Psilocybin
A research article in the Palliative Care Journal investigates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Survey of 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these had used psilocybin before (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be part of medical treatment. 84.8% endorse the public healthcare system’s provision of this therapy. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These findings align with surveys from Canada, England, and Australia. The researchers highlighted the uniqueness of their study as it focuses on the use of psychoactive substances for managing existential distress in end-of-life situations.
Why Canadians Support Psilocybin Use
An increasing number of Canadians are endorsing the use of psilocybin as a therapeutic tool, influenced largely by evidence from esteemed research institutions. Another contributing factor is the perceived safety of psilocybin mushrooms in easing existential distress. Subjects across different studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Method | Results |
| Johns Hopkins Study | Administered a high dose of psilocybin and a low dose as an active placebo control to 51 patients | Immediate and sustained |
| The benefits of this therapy extend for up to six months or even longer. The leading cause of its effectiveness is the mystical experiences that it induces, which are often characterized by a profound sense of unity and deep emotional insights. | ||
| Trial at New York University | 29 patients were arbitrarily assigned to receive either psilocybin or the active placebo, niacin. | The results of this trial were consistent with those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a newfound perspective on life and death. |
| BMC Palliative Care | Nineteen participants, including 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The objective of the study was to comprehend how palliative care professionals perceive existential distress and their perspective on psychedelic therapy as a potential treatment option. | Palliative care practitioners suggest that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Apart from scientific studies, there are multiple patient narratives that support the effectiveness of psilocybin in promoting mental wellbeing and enhancing life quality.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature, and accompanied by whimsical creatures. This vision instills a profound understanding of the universe’s interconnectedness and support, bringing her immense peace and acceptance.
Despite availing traditional mental health support, Yokoi continued to grapple with severe anxiety and distress following her diagnosis. Psilocybin therapy facilitated her reconnection with her body and offered a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare at the time of the study and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization post therapy. When asked about any alterations in her religious or spiritual beliefs since her therapy session, she stated that the experiences had infused her beliefs with meaning and reality.
Brenda’s Journey
Brenda, a lady in her sixth decade of life, was diagnosed with stage I colon cancer. She had never taken hallucinogens before and was determined to have Chronic Adjustment Disorder with an additional component of anxiety, as per her screening results.
In the course of her therapeutic sessions, Brenda encountered the sensation of death twice. Emerging from these experiences, she no longer feared death, instead viewing it as a natural part of the cycle of life. Brenda attributed her therapeutic journey from childhood trauma to the study. Her data reflected this significant transformation.
Notably, her anxiety levels and fear of death decreased while her spirituality increased.
Options for Magic Mushroom Products in Canada
At present, access to psilocybin capsules and related products designed for managing existential distress or other mental health conditions may be limited. However, reliable online dispensaries can provide these products when necessary.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Originally from Brazil and certain surrounding South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which became famous in the 1970s. |
| Potency | Average potency; suitable for beginners. | Similarly moderate potency; perfect for novices. | Exceptionally potent; advised for those with a moderate to high level of experience. |
| Effects | Produces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and better focus. | Triggers an energizing, prolonged high, minor visual changes, heightened creativity, euphoria, a gentle physical high, fractal images, and sensations of happiness. | Induces profound shamanic experiences, vision quests, intense mystical experiences, enhanced creativity, focus, social awareness, and mood improvement. |
Easing End-of-life Discomfort with Psilocybin Products
Existential distress at the end of life can significantly impact many patients as they near the end of their journey. Conventional treatments may not always effectively address this distress, leading to growing support in Canada for the inclusion of magic mushrooms in public healthcare. This increase in public interest could
We encourage regulatory authorities to view magic mushrooms as a feasible alternative for treatment. Source your psychedelics and mushroom delivery from Buy Magic Mushrooms Canada.
Frequently Asked Questions
What can patients expect from Psilocybin-Assisted Therapy?
Experiences with Psychedelic-assisted therapy (PAT) can greatly differ among patients, and following specific guidelines and careful preparation are crucial for a positive outcome. Before taking the substance, patients must undergo thorough screening and mental readiness.
- Preparation before the Session: An extensive evaluation is conducted on patients. The therapist talks to the patient about their goals and expectations to set intentions for the session. The therapist outlines the effect of the process and what the patient should expect during the session.
- The Session: In a comfortable, distraction-free environment, patients receive a controlled dose of the substance, promoting relaxation and introspection. Throughout this, the therapist provides ongoing support and guidance.
- Post-Session Integration Therapy: This therapy helps the patient to understand and process the experiences they’ve had. Future sessions offer continuous counselling and support to reinforce the insights gained and transformations made during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, notably the 5-HT2A receptor. This interaction can cause changes in perception, mood, and cognition, resulting in significant alterations in consciousness, emotional breakthroughs, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Individuals with certain mental health problems or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
